Insulet/$PODD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Insulet
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
Ticker
$PODD
Sector
Health
Primary listing
Employees
3,900
Headquarters
Website
Insulet Metrics
BasicAdvanced
$22B
93.18
$3.32
1.35
-
Price and volume
Market cap
$22B
Beta
1.35
52-week high
$329.33
52-week low
$180.31
Average daily volume
666K
Financial strength
Current ratio
2.257
Quick ratio
1.55
Long term debt to equity
68.098
Total debt to equity
99.59
Interest coverage (TTM)
7.91%
Profitability
EBITDA (TTM)
489.2
Gross margin (TTM)
70.75%
Net profit margin (TTM)
10.01%
Operating margin (TTM)
17.26%
Effective tax rate (TTM)
12.78%
Revenue per employee (TTM)
$610,000
Management effectiveness
Return on assets (TTM)
7.75%
Return on equity (TTM)
19.18%
Valuation
Price to earnings (TTM)
93.182
Price to revenue (TTM)
9.217
Price to book
14.9
Price to tangible book (TTM)
16.65
Price to free cash flow (TTM)
55.449
Free cash flow yield (TTM)
1.80%
Free cash flow per share (TTM)
5.584
Growth
Revenue change (TTM)
25.99%
Earnings per share change (TTM)
-38.92%
3-year revenue growth (CAGR)
26.05%
10-year revenue growth (CAGR)
24.86%
3-year earnings per share growth (CAGR)
88.46%
10-year earnings per share growth (CAGR)
15.71%
What the Analysts think about Insulet
Analyst ratings (Buy, Hold, Sell) for Insulet stock.
Insulet Financial Performance
Revenues and expenses
Insulet Earnings Performance
Company profitability
Insulet News
AllArticlesVideos
Insulet Lifts Annual Forecast On Increased Adoption For Insulin Pump Omnipod 5
Benzinga·6 days ago
Insulet Reports Second Quarter 2025 Revenue Increase of 32.9% Year-Over-Year (31.3% Constant Currency1)
Business Wire·7 days ago
Insulet to Announce Second Quarter 2025 Financial Results on August 7, 2025
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Insulet stock?
Insulet (PODD) has a market cap of $22B as of August 14, 2025.
What is the P/E ratio for Insulet stock?
The price to earnings (P/E) ratio for Insulet (PODD) stock is 93.18 as of August 14, 2025.
Does Insulet stock pay dividends?
No, Insulet (PODD) stock does not pay dividends to its shareholders as of August 14, 2025.
When is the next Insulet dividend payment date?
Insulet (PODD) stock does not pay dividends to its shareholders.
What is the beta indicator for Insulet?
Insulet (PODD) has a beta rating of 1.35. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.